While the exact number of people with chronic kidney disease in South Africa is unclear, estimates suggest it could be as ...

Chronic Kidney Disease is a silent killer that progresses gradually, often going unnoticed until the late stages. While ...

Weight loss drugs like Ozempic deliver more health benefits than expected.

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial. The Danish ...

While Metformin continues to be the standard first-line treatment for Type-2 diabetes, newer therapies such as SGLT2 ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Empagliflozin is a SGLT-2 inhibitor and it has shown to significantly reduce the progression of kidney disease and heart failure.

Currently priced at Rs 60 per tablet, Empagliflozin’s generic versions will be available for as low as Rs 9-Rs 14 per tablet, significantly reducing costs for millions of patients, states the report.

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...